398 related articles for article (PubMed ID: 9696377)
1. New aspects of immunotherapy of leptomeningeal metastasis.
Herrlinger U; Weller M; Schabet M
J Neurooncol; 1998; 38(2-3):233-9. PubMed ID: 9696377
[TBL] [Abstract][Full Text] [Related]
2. Treatment of leptomeningeal carcinomatosis with continuous intraventricular infusion of recombinant interleukin-2.
Heimans JJ; Wagstaff J; Schreuder WO; Wolbers JG; Baars JW; Polman CH; Scharenberg JG; Scheper RJ; Palmer PA; Franks CR
Surg Neurol; 1991 Mar; 35(3):244-7. PubMed ID: 1996455
[TBL] [Abstract][Full Text] [Related]
3. Intrathecal treatment of C6 glioma leptomeningeal metastasis in Wistar rats with interleukin-2.
Herrlinger U; Buchholz R; Jachimczak P; Schabet M
J Neurooncol; 1996 Mar; 27(3):193-203. PubMed ID: 8847552
[TBL] [Abstract][Full Text] [Related]
4. Intrathecal administration of interleukin-2 for meningeal carcinomatosis due to malignant melanoma: sequential evaluation of intracranial pressure, cerebrospinal fluid cytology, and cytokine induction.
Samlowski WE; Park KJ; Galinsky RE; Ward JH; Schumann GB
J Immunother Emphasis Tumor Immunol; 1993 Jan; 13(1):49-54. PubMed ID: 8435432
[TBL] [Abstract][Full Text] [Related]
5. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
6. Animal models of leptomeningeal metastasis.
Schabet M; Herrlinger U
J Neurooncol; 1998; 38(2-3):199-205. PubMed ID: 9696372
[TBL] [Abstract][Full Text] [Related]
7. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
8. Cytokine responses to intraventricular injection of interleukin 2 into patients with leptomeningeal carcinomatosis: rapid induction of tumor necrosis factor alpha, interleukin 1 beta, interleukin 6, gamma-interferon, and soluble interleukin 2 receptor (Mr 55,000 protein).
List J; Moser RP; Steuer M; Loudon WG; Blacklock JB; Grimm EA
Cancer Res; 1992 Mar; 52(5):1123-8. PubMed ID: 1737371
[TBL] [Abstract][Full Text] [Related]
9. [Intrathecal immune response in meningeosis neoplastica: IgG, IgM, oligoclonal bands and cytokines].
Weller M; Stevens A; Sommer N; Wiethölter H
Nervenarzt; 1992 Apr; 63(4):213-7. PubMed ID: 1594086
[TBL] [Abstract][Full Text] [Related]
10. Therapy of leptomeningeal metastasis in solid tumors.
Mack F; Baumert BG; Schäfer N; Hattingen E; Scheffler B; Herrlinger U; Glas M
Cancer Treat Rev; 2016 Feb; 43():83-91. PubMed ID: 26827696
[TBL] [Abstract][Full Text] [Related]
11. Intrathecal cytotoxic T-cell immunotherapy for metastatic leptomeningeal melanoma.
Clemons-Miller AR; Chatta GS; Hutchins L; Angtuaco EJ; Ravaggi A; Santin AD; Cannon MJ
Clin Cancer Res; 2001 Mar; 7(3 Suppl):917s-924s. PubMed ID: 11300492
[TBL] [Abstract][Full Text] [Related]
12. [Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2].
Nakano E; Iwasaki A; Seguchi T; Sugao H; Tada Y; Matsuda M; Sonoda T
Nihon Hinyokika Gakkai Zasshi; 1991 Mar; 82(3):395-404. PubMed ID: 2072602
[TBL] [Abstract][Full Text] [Related]
13. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma.
Law TM; Motzer RJ; Mazumdar M; Sell KW; Walther PJ; O'Connell M; Khan A; Vlamis V; Vogelzang NJ; Bajorin DF
Cancer; 1995 Sep; 76(5):824-32. PubMed ID: 8625186
[TBL] [Abstract][Full Text] [Related]
14. Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single-arm study.
Pan Z; Yang G; He H; Zhao G; Yuan T; Li Y; Shi W; Gao P; Dong L; Li Y
Int J Cancer; 2016 Oct; 139(8):1864-72. PubMed ID: 27243238
[TBL] [Abstract][Full Text] [Related]
15. Evidence for intrathecal sodium butyrate as a novel option for leptomeningeal metastasis.
Nakagawa H; Yui Y; Sasagawa S; Itoh K
J Neurooncol; 2018 Aug; 139(1):43-50. PubMed ID: 29626288
[TBL] [Abstract][Full Text] [Related]
16. [Management of Drug Therapy for Leptomeningeal Metastasis of Sensitive Driver Gene Positive Non-small Cell Lung Cancer].
Lu Z; Cai J; Zeng Z; Liu A
Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):710-718. PubMed ID: 32758347
[TBL] [Abstract][Full Text] [Related]
17. Adoptive immunotherapy of human meningeal gliomatosis and carcinomatosis with LAK cells and recombinant interleukin-2.
Shimizu K; Okamoto Y; Miyao Y; Yamada M; Ushio Y; Hayakawa T; Ikeda H; Mogami H
J Neurosurg; 1987 Apr; 66(4):519-21. PubMed ID: 3494108
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor.
Teichmann JV; Ludwig WD; Thiel E
Leuk Res; 1992; 16(3):287-98. PubMed ID: 1560676
[TBL] [Abstract][Full Text] [Related]
19. Enhanced survival of IFN-alpha augmented IL-2 therapy of pulmonary metastases: efficacy comparable to interleukin-2 and lymphokine activated killer cells.
Kim B; Warnaka P
J Surg Res; 1991 Jan; 50(1):40-6. PubMed ID: 1987429
[TBL] [Abstract][Full Text] [Related]
20. Interleukin 2 protects hairy leukemic cells from lymphokine-activated killer cell-mediated cytotoxicity.
Reiter Z; Taylor MW
Cancer Res; 1993 Aug; 53(15):3555-60. PubMed ID: 7687924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
